利妥昔单抗联合贝利尤单抗治疗严重难治性SLE的2年结果
本研究为2期概念验证研究的长期随访,纳入15例SLE患者(12例为狼疮肾炎),评估利妥昔单抗联合贝利尤单抗的免疫学效应与可行性。结果显示67%患者达到狼疮低疾病活动状态,75%肾炎患者出现肾脏反应,CD19+ B细胞持续减少,自身抗体显著下降。
要点
- 联合B细胞靶向治疗可阻止B细胞完全重建,包括双阴性B细胞。
- 难治性SLE患者中观察到免疫学和临床获益,值得进一步研究。
- 非应答者CD20+ B细胞清除较少且双阴性B细胞重建更早。
核心结论
- 利妥昔单抗联合贝利尤单抗可阻止B细胞完全重建并特异性降低SLE相关自身抗体。
- 在难治性SLE人群中观察到免疫学和临床获益,提示需进一步研究。
研究设计与样本
- 2期概念验证研究的长期随访,纳入15例SLE患者,其中12例(80%)为狼疮肾炎。
主要发现
- 10/15(67%)患者达到狼疮低疾病活动状态,其中8例(53%)完成2年随访。
- 12例狼疮肾炎患者中9例(75%)出现肾脏反应,包括8例(67%)完全肾脏反应。
- 所有抗dsDNA阳性患者转为阴性,抗C1q和可提取核抗原自身抗体显著下降。
- CD19+ B细胞中位较基线下降97%(24周),持续下降84%至104周。
- 非应答者CD20+ B细胞清除显著较少,双阴性B细胞重建显著更早。
临床怎么用
- 对于严重难治性SLE(尤其伴狼疮肾炎),可考虑利妥昔单抗联合贝利尤单抗的B细胞靶向策略。
- 治疗中需监测B细胞亚群重建及自身抗体变化以评估应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-CD20 B-cell depletion has not shown superior efficacy to standard immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial design, potential explanations are incomplete B-cell depletion in relation to substantial surges in B-cell-activating factor (BAFF). To improve B-cell targeting strategies, we conducted the first study in SLE patients aimed at investigating immunological effects and feasibility of combining rituximab (RTX; anti-CD20) and belimumab (BLM; anti-BAFF). METHODS: Reported is the long-term follow-up of a Phase 2 proof-of-concept study in 15 patients with SLE including 12 (80%) with lupus nephritis (LN). RESULTS: In 10/15 (67%) patients, a clinical response was observed by achievement of lupus low disease activity state, of which 8 (53%) continued treatment (BLM + ≤7.5 mg prednisolone) for the complete 2 years of follow-up. Five patients (33%) were referred to as 'non-responders' due to persistent LN, major flare or repetitive minor flares. Out of 12 LN patients, 9 (75%) showed a renal response including 8 (67%) complete renal responders. All anti-dsDNA+ patients converted to negative, and both anti-C1q and extractable nuclear antigen autoantibodies showed significant reductions. CD19+ B cells showed a median decrease from baseline of 97% at 24 weeks, with a persistent reduction of 84% up to 104 weeks. When comparing responders with non-responders, CD20+ B cells were depleted significantly less in non-responders and double-negative (DN) B cells repopulated significantly earlier. CONCLUSIONS: Combined B-cell targeted therapy with RTX and BLM prevented full B-cell repopulation including DN B cells, with concomitant specific reduction of SLE-relevant autoantibodies. The observed immunological and clinical benefits in a therapy-refractory SLE population prompt further studies on RTX + BLM.
引用
- Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021. PMID: 32591783. doi:10.1093/ndt/gfaa117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。